BioVie (NASDAQ:BIVI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioVie (NASDAQ:BIVI) to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioVie in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

BioVie Stock Performance

Shares of NASDAQ:BIVI opened at $1.43 on Friday. The company has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $1.47. The stock has a market capitalization of $10.74 million, a price-to-earnings ratio of -0.58 and a beta of 0.57. BioVie has a one year low of $1.06 and a one year high of $8.84.

BioVie (NASDAQ:BIVI) last released its earnings results on Monday, May 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in BioVie in the fourth quarter valued at about $25,000. Two Sigma Investments LP acquired a new stake in shares of BioVie in the 3rd quarter worth approximately $62,000. Squarepoint Ops LLC acquired a new stake in shares of BioVie in the 3rd quarter worth approximately $63,000. NewEdge Advisors LLC increased its stake in BioVie by 283.7% in the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock valued at $53,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in BioVie in the 2nd quarter valued at approximately $57,000. 4.59% of the stock is currently owned by institutional investors and hedge funds.

BioVie Company Profile

BioVie Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver?related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life?threatening condition marked by elevated neurotoxins in patients with advanced liver disease.